Abcellera Biologics Inc (ABCL) — Capital Reinvestment Ratio
Abcellera Biologics Inc (ABCL) has a Capital Reinvestment Ratio of 1.38x as of June 2023, meaning it reinvests 1% of its operating cash flow ($19.82 Million) in capital expenditures ($27.35 Million). Check tangible equity quality of Abcellera Biologics Inc to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Abcellera Biologics Inc Capital Reinvestment Ratio (2018–2022)
This chart tracks Abcellera Biologics Inc's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see Abcellera Biologics Inc (ABCL) cash conversion ratio.
Annual Capital Reinvestment Ratio for Abcellera Biologics Inc (2018–2022)
Year-by-year Capital Reinvestment Ratio for Abcellera Biologics Inc from 2018 to 2022. See Abcellera Biologics Inc (ABCL) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.26x | $277.36 Million | $72.66 Million | ▲ +9.6% |
| 2021 | 0.24x | $244.58 Million | $58.45 Million | ▼ -63.0% |
| 2020 | 0.65x | $22.69 Million | $14.67 Million | ▼ -56.4% |
| 2019 | 1.48x | $2.69 Million | $4.00 Million | ▼ -0.3% |
| 2018 | 1.49x | $3.56 Million | $5.31 Million | — |